Literature DB >> 2302272

Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis.

P J Brooks1, W J Spruill, R C Parish, D A Birchmore.   

Abstract

The serum concentrations and the pharmacokinetics of low-dose methotrexate (MTX) were compared after both intramuscular (IM) and subcutaneous (SQ) injections in 5 patients with rheumatoid arthritis. Values for the observed peak concentration, the time to the observed peak concentration, and the area under the time versus concentration curve for IM injections were not significantly different from these values for SQ injections. These results suggest that IM and SQ are interchangeable routes of administration. SQ administration may be a more convenient and less painful way of administering low-dose MTX.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2302272     DOI： 10.1002/art.1780330112

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


  20 in total

1.  Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin.

Authors:  D J Chatterjee; W Y Li; R T Koda
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 2.  Efficacy of methotrexate in ulcerative colitis: failure or promise.

Authors:  Hans H Herfarth; Mark T Osterman; Kim L Isaacs; James D Lewis; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

5.  Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.

Authors:  Ray Fitzpatrick; David Gi Scott; Ian Keary
Journal:  Clin Rheumatol       Date:  2013-07-09       Impact factor: 2.980

6.  Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation.

Authors:  Frank Striesow; Andreas Brandt
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 7.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Methotrexate for induction of remission in refractory Crohn's disease.

Authors:  John W D McDonald; Yongjun Wang; David J Tsoulis; John K MacDonald; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2014-08-06

9.  Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis.

Authors:  Ulf Müller-Ladner; Karin Rockwitz; Jan Brandt-Jürgens; Roland Haux; Peter Kästner; Jürgen Braun; Winfried Demary; Cécile Guimbal-Schmolck; Uwe Pichlmeier; Andreas Brandt
Journal:  Open Rheumatol J       Date:  2010-03-18

10.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.